ArticleBMC chemistry2025
A new chromatographic approach for the simultaneous determination of tramadol, ibuprofen, and caffeine in a novel fixed-dose combination tablet: an integrated framework to analytical sustainability and multimodal analgesia.
Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multimodal analgesia and rational polypharmacy have emerged as modern pain management strategies, offering synergistic pain relief while mitigating the adverse effects of high-dose monotherapy. A novel antinociceptive fixed-dose combination tablet containing tramadol, ibuprofen, and caffeine exemplifies this approach by integrating a centrally acting weak opioid tramadol, a peripherally acting nonsteroidal anti-inflammatory drugs ibuprofen, and a central nervous system stimulant adjuvant caffeine into a single formulation. In the present work, the first HPLC method for the concurrent quantification of tramadol, ibuprofen and caffeine in bulk powder and tablet dosage forms was developed and validated to support the quality control of this innovative multimodal analgesic fixed-dose combination. The optimal chromatographic separation was achieved using a Zorbax SD-C8 column (150 × 4.6 mm, 5 µm) as the stationary phase. The mobile phase was composed of acetonitrile: 0.01 M phosphate buffer pH 5.0 (35.0: 65.0, v/v), delivered at a flow rate of 1.0 mL/min with UV detection at 220.0 nm. The separation was achieved within 8.0 min, with linearity ranges of 1.0-45.0 μg/mL for tramadol, 1.0-25.0 μg/mL for ibuprofen, and 1.0-30.0 µg/mL for caffeine. The suggested method was validated according to the ICH guidelines and successfully utilized for the quantitative determination of tramadol, ibuprofen and caffeine in bulk powder, laboratory-prepared mixtures and pharmaceutical formulation. The proposed method exhibited outstanding performance for determination of the three cited drugs, characterized by high accuracy (ranging from 100.42% to 100.82%) and excellent precision (< 2% RSD). The sustainability profile of the method was assessed using the Analytical eco-scale, Analytical GREEnness metric, Green analytical procedure index, Blue Applicability Grade Index, White analytical chemistry, and Violet Innovation Grade Index to evaluate the sustainability, applicability, and innovative potential of the proposed method. The method combines analytical rigor, operational simplicity, and sustainable design, setting a new benchmark for analytical support of rational polypharmacy products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.